v3.26.1
Segment Reporting (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
USD ($)
Mar. 31, 2026
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Jun. 30, 2026
USD ($)
segment
Jun. 30, 2025
USD ($)
Segment Reporting            
Number of operating segments | segment         1  
Number of reportable segments | segment         1  
Revenue $ 13,475   $ 13,459   $ 24,260 $ 24,156
Cost of product revenue 2,011   1,944   3,340 3,206
Research & Development            
Stock-based compensation 14,649   9,678   30,231 20,134
Depreciation         3,134 2,007
Interest income 5,449   3,455   11,500 7,282
Interest expense (2,792)   (3,016)   (5,569) (6,000)
Net loss (78,763) $ (88,612) (67,814) $ (64,053) (167,375) (131,867)
Single reportable segment            
Segment Reporting            
Revenue 13,475   13,459   24,260 24,156
Cost of product revenue 2,011   1,944   3,340 3,206
Research & Development            
AXPAXLI 28,756   33,158   71,216 57,613
Direct program expenses, Other clinical and preclinical programs 716   1,001   1,475 2,081
Unallocated expenses, Personnel costs 13,538   9,350   26,514 18,689
Unallocated expenses, All other costs 2,081   2,039   3,890 4,925
Selling and marketing 15,079   12,477   29,153 25,251
General and administrative 14,416   8,649   26,022 18,301
Facilities 2,487   1,777   4,758 3,508
Stock-based compensation 14,649   9,678   30,231 20,134
Depreciation 1,851   1,027   3,111 2,007
Interest income 5,449   3,455   11,500 7,282
Interest expense (2,792)   (3,016)   (5,569) (6,000)
Other non-operating items 689   (612)   2,144 (1,590)
Net loss $ (78,763)   $ (67,814)   $ (167,375) $ (131,867)